RELATIONSHIP BETWEEN INTACT 1-84-PARATHYROID-HORMONE AND BONE HISTOMORPHOMETRIC PARAMETERS IN DIALYSIS PATIENTS WITHOUT ALUMINUM TOXICITY

被引:193
作者
WANG, M
HERCZ, G
SHERRARD, DJ
MALONEY, NA
SEGRE, GV
PEI, Y
机构
[1] VET ADM MED CTR,DEPT MED,SEATTLE,WA
[2] UNIV WASHINGTON,SEATTLE,WA 98195
[3] UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA
[4] MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114
关键词
OSTEODYSTROPHY; BONE; PARATHYROID HORMONE; RENAL FAILURE;
D O I
10.1016/0272-6386(95)90453-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
With the markedly reduced usage of aluminum salts in renal failure, parathyroid hormone (PTH) has become the major determinant of currently seen bone disease. Clinicians now must consider what PTH level should be sought, Too low a level may lead to the aplastic bone lesion (low turnover bone), and too high a level may cause osteitis fibrosa, Furthermore, conventional normal PM levels may not be a suitable target because of the well-known resistance to PTH in uremic patients. In this report, we derive the PTH levels that best distinguish patients with low and high bone formation states from those with normal bone formation in a group of 175 dialysis patients without aluminum toxicity, Using bone histological parameters, we propose that ideally PTH levels should be maintained between 10 pmol/L (100 pg/mL) and 20 to 30 pmol/L (200 to 300 pg/mL) in chronic dialysis patients, levels two to four times the upper limit of values found in normal subjects. (C) 1995 by the National Kidney Foundation, Inc.
引用
收藏
页码:836 / 844
页数:9
相关论文
共 32 条
[1]  
ANDRESS DL, 1986, J BONE MINER RES, V1, P391
[2]   SERUM BONE GLA-PROTEIN IN RENAL OSTEODYSTROPHY - COMPARISON WITH BONE HISTOMORPHOMETRY [J].
CHARHON, SA ;
DELMAS, PD ;
MALAVAL, L ;
CHAVASSIEUX, PM ;
ARLOT, M ;
CHAPUY, MC ;
MEUNIER, PJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (04) :892-897
[3]  
EKE F U, 1988, Child Nephrology and Urology, V9, P33
[4]   SERUM AND URINARY MARKERS OF BONE REMODELING - ASSESSMENT OF BONE TURNOVER [J].
EPSTEIN, S .
ENDOCRINE REVIEWS, 1988, 9 (04) :437-449
[5]   SERUM AND DIALYSATE OSTEOCALCIN LEVELS IN HEMODIALYSIS AND PERITONEAL-DIALYSIS PATIENTS AND AFTER RENAL-TRANSPLANTATION [J].
EPSTEIN, S ;
TRABERG, H ;
RAJA, R ;
POSER, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (06) :1253-1256
[6]   STAINABLE ALUMINUM AND NOT ALUMINUM CONTENT REFLECTS BONE-HISTOLOGY IN DIALYZED PATIENTS [J].
FAUGERE, MC ;
MALLUCHE, HH .
KIDNEY INTERNATIONAL, 1986, 30 (05) :717-722
[7]   OSTEOCALCIN IN HUMAN-SERUM - A CIRCADIAN-RHYTHM [J].
GUNDBERG, CM ;
MARKOWITZ, ME ;
MIZRUCHI, M ;
ROSEN, JF .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (04) :736-739
[8]   APLASTIC OSTEODYSTROPHY WITHOUT ALUMINUM - THE ROLE OF SUPPRESSED PARATHYROID FUNCTION [J].
HERCZ, G ;
PEI, Y ;
GREENWOOD, C ;
MANUEL, A ;
SAIPHOO, C ;
GOODMAN, WG ;
SEGRE, GV ;
FENTON, S ;
SHERRARD, DJ .
KIDNEY INTERNATIONAL, 1993, 44 (04) :860-866
[9]  
HERCZ G, 1994, J AM SOC NEPHROL, V5, pA851
[10]  
HERCZ G, 1993, J AM SOC NEPHROL, V4, pA697